OrsoBio announces positive topline Phase 1b/2a clinical data for its oral mitochondrial protonophore TLC-6740 in combination ...
31mon MSN
Is Eli Lilly a buy before 2026?
Eli Lilly’s next-generation obesity treatment may prove highly effective for patients who have high BMI or suffer from ...
The best weight loss medication for men includes semaglutide (Ozempic , Wegovy ), tirzepatide (Mounjaro , Zepbound ), and ...
In patients with coronary artery disease (CAD) and obesity, tirzepatide was associated with lower mortality and reduced ...
MedPage Today on MSN
One GLP-1 Drug May Be Better Than Rivals for Glaucoma Risk
Use of the dual GIP/GLP-1 drug tirzepatide (Mounjaro, Zepbound) was associated with a significantly reduced risk of glaucoma ...
The SURMOUNT-1 trial evaluated Tirzepatide a dual GIP/GLP1 agonist, in individuals with overweight (BMI more than or equal to ...
The move broadens treatment choices for pediatric patients aged 10 years and older whose diabetes remains uncontrolled with ...
Using tirzepatide is linked to lower risks of developing primary open-angle glaucoma and elevated eye pressure in patients ...
3don MSNOpinion
Lawmakers must expand coverage for obesity treatment
Congress has the power to make obesity treatment and weight management accessible to the communities that need it.
Trials have shown that semaglutide can reduce major cardiovascular events, but the extent of tirzepatide’s heart protection has been less clear. A team at Mass General Brigham set out to compare both ...
The five-year SURMOUNT-REAL UK trial, part of a collaboration signed last year between Lilly and the UK government, will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results